These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Angioedema without wheals: a clinical update. Gülbahar O Balkan Med J; 2021 Mar; 38(2):73-81. PubMed ID: 33593719 [TBL] [Abstract][Full Text] [Related]
44. Novelties in the Diagnosis and Treatment of Angioedema. Cicardi M; Suffritti C; Perego F; Caccia S J Investig Allergol Clin Immunol; 2016; 26(4):212-21; quiz two pages after page 221. PubMed ID: 27470642 [TBL] [Abstract][Full Text] [Related]
48. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy. Hakl R; Kuklínek P; Krčmová I; Králíčková P; Freiberger T; Janků P; Vlková M; Litzman J J Clin Immunol; 2018 Oct; 38(7):810-815. PubMed ID: 30280305 [TBL] [Abstract][Full Text] [Related]
49. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Cicardi M; Zingale LC; Pappalardo E; Folcioni A; Agostoni A Medicine (Baltimore); 2003 Jul; 82(4):274-81. PubMed ID: 12861105 [TBL] [Abstract][Full Text] [Related]
50. Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Cugno M; Castelli R; Cicardi M Autoimmun Rev; 2008 Dec; 8(2):156-9. PubMed ID: 19014872 [TBL] [Abstract][Full Text] [Related]
51. Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship. Castelli R; Zanichelli A; Cicardi M; Cugno M Crit Rev Oncol Hematol; 2013 Sep; 87(3):323-32. PubMed ID: 23490322 [TBL] [Abstract][Full Text] [Related]
52. The acquired deficiency of C1-inhibitor: lymphoproliferation and angioedema. Cicardi M; Zanichelli A Curr Mol Med; 2010 Jun; 10(4):354-60. PubMed ID: 20455857 [TBL] [Abstract][Full Text] [Related]
53. An evidence based therapeutic approach to hereditary and acquired angioedema. Bork K Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294 [TBL] [Abstract][Full Text] [Related]
54. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant. Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O; Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922 [TBL] [Abstract][Full Text] [Related]
55. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency. Zanichelli A; Wu MA; Andreoli A; Mansi M; Cicardi M Expert Opin Drug Saf; 2015; 14(11):1725-36. PubMed ID: 26429506 [TBL] [Abstract][Full Text] [Related]
56. Hereditary angioedema due to C1-inhibitor deficiency in Macedonia: clinical characteristics, novel SERPING1 mutations and genetic factors modifying the clinical phenotype. Grivčeva-Panovska V; Košnik M; Korošec P; Andrejević S; Karadža-Lapić L; Rijavec M Ann Med; 2018 May; 50(3):269-276. PubMed ID: 29513108 [TBL] [Abstract][Full Text] [Related]
57. [Recurrent isolated angioedema as a result of acquired C1 inhibitor deficiency]. Bosma J; Bijl JM; Siegert CE; Vasmel WL Ned Tijdschr Geneeskd; 2014; 158():A7184. PubMed ID: 24666532 [TBL] [Abstract][Full Text] [Related]
58. Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema. Riedl MA; Lumry WR; Li HH; Craig TJ; Fitts D; Kalfus I; Uknis ME Am J Rhinol Allergy; 2013; 27(6):517-21. PubMed ID: 24274230 [TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema. Lumry W; Soteres D; Gower R; Jacobson KW; Li HH; Chen H; Schranz J Pediatr Allergy Immunol; 2015 Nov; 26(7):674-80. PubMed ID: 26171584 [TBL] [Abstract][Full Text] [Related]